- Home
- CVKD vs ALLK Comparison
CVKD vs ALLK Comparison
Compare CVKD & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- ALLK
- Stock Information
- Founded
- CVKD 2022
- ALLK 2012
- Country
- CVKD United States
- ALLK United States
- Employees
- CVKD N/A
- ALLK N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- ALLK Health Care
- Exchange
- CVKD Nasdaq
- ALLK Nasdaq
- Market Cap
- CVKD 33.7M
- ALLK 29.5M
- IPO Year
- CVKD 2023
- ALLK 2018
- Fundamental
- Price
- CVKD $15.50
- ALLK $0.33
- Analyst Decision
- CVKD Strong Buy
- ALLK Hold
- Analyst Count
- CVKD 1
- ALLK 3
- Target Price
- CVKD $32.00
- ALLK $2.00
- AVG Volume (30 Days)
- CVKD 21.0K
- ALLK 743.7K
- Earning Date
- CVKD 05-08-2025
- ALLK 05-20-2025
- Dividend Yield
- CVKD N/A
- ALLK N/A
- EPS Growth
- CVKD N/A
- ALLK N/A
- EPS
- CVKD N/A
- ALLK N/A
- Revenue
- CVKD N/A
- ALLK N/A
- Revenue This Year
- CVKD N/A
- ALLK N/A
- Revenue Next Year
- CVKD N/A
- ALLK N/A
- P/E Ratio
- CVKD N/A
- ALLK N/A
- Revenue Growth
- CVKD N/A
- ALLK N/A
- 52 Week Low
- CVKD $5.70
- ALLK $0.22
- 52 Week High
- CVKD $22.90
- ALLK $1.56
- Technical
- Relative Strength Index (RSI)
- CVKD 41.03
- ALLK 59.99
- Support Level
- CVKD $15.29
- ALLK $0.32
- Resistance Level
- CVKD $17.00
- ALLK $0.33
- Average True Range (ATR)
- CVKD 0.80
- ALLK 0.00
- MACD
- CVKD -0.02
- ALLK -0.00
- Stochastic Oscillator
- CVKD 9.50
- ALLK 79.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.